Tsukagoshi Eri, Tanaka Yoichi, Saito Yoshiro
Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan.
Front Med (Lausanne). 2021 Mar 24;8:644154. doi: 10.3389/fmed.2021.644154. eCollection 2021.
Drug-related Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but severe adverse drug reactions, termed as idiosyncratic reactions; however, predicting their onset remains challenging. Pharmacogenomic information associated with SJS/TEN has accumulated on several drugs in the last 15 years, with clinically useful information now included on drug labels in several countries/regions or guidelines of the Clinical Pharmacogenetics Implementation Consortium (CPIC) for implementation. However, label information might be different among countries. This mini-review summarizes pharmacogenomic information on drug labels of five drugs in six countries and compared descriptions of drug labels and CPIC guidelines. Finally, we discuss future perspectives of this issue. Pharmacogenomic information on drug labels is not well-harmonized across countries/regions, but CPIC guidelines are a scientifically sound goal for future pharmacogenomic implementation.
药物相关的史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症(SJS/TEN)虽罕见但严重,属于特异质性不良反应;然而,预测其发病仍然具有挑战性。在过去15年里,与SJS/TEN相关的药物基因组学信息在多种药物上有所积累,目前在一些国家/地区的药品标签或临床药物基因组学实施联盟(CPIC)的指南中纳入了具有临床实用价值的信息以供实施。然而,各国的标签信息可能有所不同。本综述总结了六个国家五种药物的药品标签上的药物基因组学信息,并比较了药品标签描述与CPIC指南。最后,我们讨论了该问题的未来展望。各国/地区药品标签上的药物基因组学信息尚未很好地协调一致,但CPIC指南是未来药物基因组学实施的科学合理目标。